Reuters logo
8 个月前
BRIEF-Aeglea Bio Therapeutics announces results of preclinical studies of AEB3103
2016年11月21日 / 下午4点16分 / 8 个月前

BRIEF-Aeglea Bio Therapeutics announces results of preclinical studies of AEB3103

1 分钟阅读

Nov 21 (Reuters) - Aeglea Bio Therapeutics Inc :

* Announced results of preclinical studies of AEB3103 showing suppressed growth of tumors in models of prostate, breast cancer

* Preclinical findings showed aeb3103 had potent anti-tumor effect in multiple solid tumor models, including prostate, breast cancer

* Preclinical findings showed that AEB3103 was well tolerated for more than five months

* Preclinical studies showed treatment with AEB3103 showed significantly longer survival in CLL animal model versus treatment with SOC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below